地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:17754422825
邮箱:sales@amyjet.com

艾美捷科技代理Prolytix品牌脂质组学和氧化脂质生物标志物相关产品。
Prolytix是一家专注于脂质组学和氧化脂质生物标志物研究的公司,致力于为生物医学研究和临床诊断提供高质量的脂质分析服务和产品。总部:位于美国佛蒙特州伯灵顿市。
Prolytix公司核心业务包括:
(1)脂质组学分析,提供全面的脂质组学分析服务,包括氧化脂质、磷脂、鞘脂等的定量和定性分析;
(2)生物标志物开发,开发和验证与疾病相关的脂质生物标志物,用于早期诊断和疾病监测;
(3)定制化解决方案:根据客户需求,提供定制化的脂质分析方案和研究服务。
Prolytix公司的产品包括氧化脂质标准品、脂质分析试剂盒、脂质组学分析软件等。Prolytix公司产品广泛应用于:
(1)生物医学研究:广泛应用于心血管疾病、癌症、神经退行性疾病等研究领域。
(2)临床诊断:支持脂质生物标志物的开发和临床应用,助力疾病早期诊断和个性化治疗。
(3)药物开发:用于药物靶点发现、药效评价和安全性评估。
<<<<< " data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Prolytix品牌"> 艾美捷科技代理Prolytix品牌
在诊断领域,Generon拥有数百个产品,主要包括抗体、组织染色切片、FISH、CISH探针、qPCR&NGS试剂盒等,针对分子生物学、二代测序、组织学、原位杂交、流式细胞学等应用,所有这些诊断产品均拥有CE/IVD认证,可以确保临床应用中的准确性。在研究领域,Generon拥有上百万个产品,主要是针对分子生物学、NGS、2D、3D细胞培养、免疫检测、色谱、电泳等实验的抗体、ELISA试剂盒等。
Generon’s catalog includes several hundred products for diagnosis and medical biology. Our products cover a wide range of applications and field of medical diagnostics. We want to offer you all the products you need to move your projects forward. Applications: molecular biology, NGS, histology, in situ hybridization, flow cytometry ... Types of products: Antibodies, tissue stains, probes for FISH and CISH, qPCR and NGS kits, culture media.... All our medical diagnostic products are CE / IVD-certified (In Vitro Diagnostic) to ensure quality and follow-up for reliable results in diagnosis and choosing the right treatment.
Generon’s catalog includes millions of products for research in the life sciences. Our products cover a wide range of applications and research areas. We want to offer you all the products you need to move your projects forward. Applications: Molecular biology, NGS, 2D and 3D cell culture, immunoassays, chromatography, electrophoresis ... Types of products: Antibodies, ELISA kits, PCR Enzymes, particles, tetramers, disinfectants ...
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Generon"> Generon
艾美捷科技特约代理Cosmo Bio公司产品。
Cosmo Bio Co., Ltd.是日本最大、最值得信赖的生命科学研究的产品供应商之一。公司成立于1983年,提供超过36万的产品。其丰富的产品种类、快捷的物流、详尽的产品资料、专业的客户支持和服务,不断的推动着生命科学的发展和进步。
Cosmo Bio provides the most up-to-date products and technical information available from world-class manufacturers, to laboratories, research institutes, life-science education and testing organizations throughout Japan and around the world. We are proud that our ability to supply a vast array of products and information allows us to serve the needs of all of our customers. By making full use of our international network, coupled with the highest quality information, we support the life sciences community with a level of commitment and responsibility befitting a company that is trusted by its valued customers.
主要产品分类:
仪器(Instruments)、细胞融合、转染、培养(Cell Fusion, Transfection, Culture)、体外翻译(In vitro Translation)、抗体(Antibodies)、检测试剂盒(ELISA & Detection Kits ELISA)、生物医学相关(Biomedical)、蛋白质、多肽&糖类(Proteins, Peptides & Sugars)、化学试剂(Chemicals)、分子生物(DNA Molecular Biology)
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Cosmo Bio公司产品"> 艾美捷科技特约代理Cosmo Bio公司产品
Dianova公司为德国著名的病理免疫组化产品供应商,具备领先的抗体制备工艺及严格的质控系统,产品在国际上享有良好的声誉。
Since its foundation in 1982, dianova GmbH provides professionals in Life Sciences with antibodies, immunoassays, and products for molecular biology. More than 30 years of grown expertise give rise to a fundamental knowledge about biochemical applications and a profound understanding of customer needs in research and routine diagnostic laboratories of universities, hospitals and the pharmaceutical industry.
Dianova公司的主要产品包括:
Proteine
Assays / Kits
Reagenzien / Medien
Material
Geräte
Antikörper-Service
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Dianova"> Dianova
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

SignalChem公司提供人类重组蛋白,用于研究细胞信号传导的生物技术领域。生产供应高活性激酶、磷酸酶、磷酸二酯酶、组蛋白脱乙酰酶、沉默信息素和参与信号转导的其他细胞蛋白、抗体、肽底物等。包括定制蛋白质开发和化合物分析。
SignalChem is a biotechnology company focused on the research, development and production of innovative cell signaling products. Our company focuses on producing highly purified biologically-active human recombinant proteins. SignalChem strives to support life scientists in academia and biotech by creating effective research tools to advance basic life sciences research and drug discovery efforts.
SignalChem公司的主要产品包括:
Active Enzymes
Antibodies
Biochemical Compounds
Signaling Proteins
Signaling Reagents
Extracellular Ligands
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="SignalChem"> SignalChem
艾美捷科技特约代理Cosmo Bio公司产品。
Cosmo Bio Co., Ltd.是日本最大、最值得信赖的生命科学研究的产品供应商之一。公司成立于1983年,提供超过36万的产品。其丰富的产品种类、快捷的物流、详尽的产品资料、专业的客户支持和服务,不断的推动着生命科学的发展和进步。
Cosmo Bio provides the most up-to-date products and technical information available from world-class manufacturers, to laboratories, research institutes, life-science education and testing organizations throughout Japan and around the world. We are proud that our ability to supply a vast array of products and information allows us to serve the needs of all of our customers. By making full use of our international network, coupled with the highest quality information, we support the life sciences community with a level of commitment and responsibility befitting a company that is trusted by its valued customers.
主要产品分类:
仪器(Instruments)、细胞融合、转染、培养(Cell Fusion, Transfection, Culture)、体外翻译(In vitro Translation)、抗体(Antibodies)、检测试剂盒(ELISA & Detection Kits ELISA)、生物医学相关(Biomedical)、蛋白质、多肽&糖类(Proteins, Peptides & Sugars)、化学试剂(Chemicals)、分子生物(DNA Molecular Biology)
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Cosmo Bio公司产品"> 艾美捷科技特约代理Cosmo Bio公司产品
艾美捷科技有限公司,代理GORYO Chemical公司全系列探针产品。
GORYO Chemical公司位于日本札幌市,是一家生产荧光探针的专业化供应商。由于荧光探针的化学特性,使得研究者可以利用它对细胞内运行机理进行可视化研究。GORYO Chemical与东京大学和北海道大学合作,在荧光试剂领域领已取得领先的地位。目前,GORYO Chemical在日本已经开始针对癌症检测推出临床使用的探针,在未来,这将为指导治疗提供新的方法。
<主要产品和服务:
| AcidiFluor™ Series | Fluorescent probes to detect acidic pH | Size |
| GC301 | AcidiFluor™ ORANGE | 10 μg × 20 |
| GC3011 | AcidiFluor™ ORANGE | 10 μg × 10 |
| GC302 | AcidiFluor™ ORANGE-NHS | 1 mg |
| GC303 | AcidiFluor™ ORANGE-NHS | 5 μg × 5 |
| GC304 | AcidiFluor™ ORANGE Labeling Kit | 5 times labeling |
| GC305 | AcidiFluor™ ORANGE-Zymosan A | 1 mg |
| GC306 | AcidiFluor™ ORANGE-Dextran 10k | 1 mg |
| GC309 | AcidiFluor™ ORANGE-Transferrin | 1 mg |
| GC310-01 | HaloTag® AcidiFluor™ ORANGE Ligand | 30 nmol |
| GC310-02 | HaloTag® AcidiFluor™ ORANGE Ligand | 60 nmol |
| CalxFluor™ Series | Fluorescent probes to detect calcium ions | Size |
| GC405 | CaSiR-1 potassium salt | 500 µg |
| GC503 | CaTM-2 AM | 500 μg |
| GC504 | CaTM-2 AM | 50 μg × 10 |
| GC5041 | CaTM-2 AM | 50 μg × 5 |
| GC507 | CaTM-3 AM | 40 nmol × 5 |
| GlycoFluor™ Series | Fluorescent probes to detect glycosidase activity | Size |
| GC601 | GlycoYELLOW™ –βGal | 50 μg × 10 |
| GC611 | GlycoGREEN™-βGal | 30 nmol × 5 |
| SK4001-01 | TokyoGreen®–βGal | 1 mg |
| SK4002-01 | TokyoGreen®–βGlu | 1 mg |
| SK4003-01 | TokyoGreen®–βGlcU(Na) | 1 mg |
| HaloFluor™ Series | Fluorescent probes combined with Halotag® ligand | Size |
| GC310-01 | HaloTag® AcidiFluor™ ORANGE Ligand | 30 nmol |
| GC310-02 | HaloTag® AcidiFluor™ ORANGE Ligand | 60 nmol |
| A201-01 | HaloTag® SaraFluor™ 650B ligand | 15 nmol |
| A201-02 | HaloTag ®SaraFluor™ 650B ligand | 15 nmol × 2 |
| ProteoFluor™ Series | Fluorescent probes to detect protease activity in cancer cell | Size |
| GC801 | ProteoGREEN™-gGlu | 20 μg × 10 |
| GC811 | EP-HMRG | 30 nmol x 5 |
| StemFluor™ Series | Fluorescent probes to detect human iPS/ES cells | Size |
| GC7001-01 | Kyoto Probe 1 (KP-1) | 10 μg × 5 |
| GC7001-02 | Kyoto Probe 1 (KP-1) | 10 μg × 10 |
| SaraFluor™ Series | Fluorescent probes for labeling/imaging | Size |
| ST1003-10 | SaraFluor™ 488-NHS | 5 nmol x 5 |
| ST1003-11 | SaraFluor™ 488-NHS | 1 mg |
| ST1003-15 | SaraFluor™ 488-NHS | 1 mg x 5 |
| ST1003-21 | SaraFluor™ 488-maleimide | 1 mg |
| ST1003-25 | SaraFluor™ 488-maleimide | 1 mg x 5 |
| ST1003-31 | SaraFluor™ 488-COOH | 1 mg |
| ST1003-35 | SaraFluor™ 488-COOH | 1 mg x 5 |
| ST1003-41 | SaraFluor™ 488-NH2 | 1 mg |
| ST1003-45 | SaraFluor™ 488-NH2 | 1 mg x 5 |
| ST1006-10 | SaraFluor™ 600-NHS | 5 nmol x 5 |
| ST1006-11 | SaraFluor™ 600-NHS | 1 mg |
| ST1006-15 | SaraFluor™ 600-NHS | 1 mg x 5 |
| ST1006-21 | SaraFluor™ 600-maleimide | 1 mg |
| ST1006-25 | SaraFluor™ 600-maleimide | 1 mg x 5 |
| ST1006-31 | SaraFluor™ 600-COOH | 1 mg |
| ST1006-35 | SaraFluor™ 600-COOH | 1 mg x 5 |
| ST1006-41 | SaraFluor™ 600-NH2 | 1 mg |
| ST1006-45 | SaraFluor™ 600-NH2 | 1 mg x 5 |
| ST1008-10 | SaraFluor™ 650-NHS | 5 nmol x 5 |
| ST1008-11 | SaraFluor™ 650-NHS | 1 mg |
| ST1008-15 | SaraFluor™ 650-NHS | 1 mg x 5 |
| ST1008-21 | SaraFluor™ 650-maleimide | 1 mg |
| ST1008-25 | SaraFluor™ 650-maleimide | 1 mg x 5 |
| ST1008-31 | SaraFluor™ 650-COOH | 1 mg |
| ST1008-35 | SaraFluor™ 650-COOH | 1 mg x 5 |
| ST1008-41 | SaraFluor™ 650-NH2 | 1 mg |
| ST1008-45 | SaraFluor™ 650-NH2 | 1 mg x 5 |
| ST1010-10 | SaraFluor™ 700-NHS | 5 nmol x 5 |
| ST1010-11 | SaraFluor™ 700-NHS | 1 mg |
| ST1010-15 | SaraFluor™ 700-NHS | 1 mg x 5 |
| ST1010-21 | SaraFluor™ 700-maleimide | 1 mg |
| ST1010-25 | SaraFluor™ 700-maleimide | 1 mg x 5 |
| ST1010-31 | SaraFluor™ 700-COOH | 1 mg |
| ST1010-35 | SaraFluor™ 700-COOH | 1 mg x 5 |
| ST1010-41 | SaraFluor™ 700-NH2 | 1 mg |
| ST1010-45 | SaraFluor™ 700-NH2 | 1 mg x 5 |
| ST1011-10 | SaraFluor™ 720-NHS | 5 nmol x 5 |
| ST1011-11 | SaraFluor™ 720-NHS | 1 mg |
| ST1011-15 | SaraFluor™ 720-NHS | 1 mg x 5 |
| ST1011-21 | SaraFluor™ 720-maleimide | 1 mg |
| ST1011-25 | SaraFluor™ 720-maleimide | 1 mg x 5 |
| ST1011-31 | SaraFluor™ 720-COOH | 1 mg |
| ST1011-35 | SaraFluor™ 720-COOH | 1 mg x 5 |
| ST1011-41 | SaraFluor™ 720-NH2 | 1 mg |
| ST1011-45 | SaraFluor™ 720-NH2 | 1 mg x 5 |
| A201-01 | HaloTag® SaraFluor™ 650B ligand | 15 nmol |
| A201-02 | HaloTag ®SaraFluor™ 650B ligand | 15 nmol × 2 |
| A202-01 | SaraFluor™ 650B goat anti-mouse IgG | 100 μg |
| A203-01 | SaraFluor™ 650B goat anti-rat IgG | 100 μg |
| A204-01 | SaraFluor™ 650B goat anti-rabbit IgG | 100 μg |
| A208-01 | SaraFluor™ 650B-NHS | 100 μg |
| A209-01 | SaraFluor™ 650B-maleimide | 100 μg |
| A218-01 | SaraFluor™ 488B-NHS | 100 μg |
| MetalloFluor™ Series | Fluorescent probes to detect metall ion | Size |
| GC901 | FeRhoNox™-1 | 50 μg × 10 |
| GC902 | CopperGREEN™ | 50 nmol × 5 |
| GC903-01 | FerroFarRed™ | 50 nmol × 5 |
| GC904-01 | FerroOrange | 35 nmol × 5 |
| GC904-02 | FerroOrange | 35 nmol × 1 |
| SK2001-01 | ZnAF®-2 | 1 mg |
| SK2002-01 | ZnAF®-2 DA | 1 mg |
| NOFluor™ Series | Fluorescent probes to detect niric oxide | Size |
| SK1001-01 | DAF-2 | 1 mg |
| SK1002-01 | DAF-2 DA | 1 mg |
| SK1003-01 | DAF-FM | 1 mg |
| SK1004-01 | DAF-FM DA | 1 mg |
| SK1005-01 | DAR-4M | 1 mg |
| SK1006-01 | DAR-4M AM | 1 mg |
| HypoFluor™ Series | Fluorescence probes for hypoxia detection | Size |
| A101-01 | MAR | 25 μg × 5 |
| ROSFluor™ Series | Fluorescent probes to detect reactive oxigen species | Size |
| SK3001-02 | Hydroxyphenyl Fluorescein (HPF) | 1 mg |
| SK3002-02 | Aminophenyl Fluorescein (APF) | 1 mg |
| SK3003-01 | NiSPY-3 | 1 mg |
| GC3004-01 | OxiORANGE™ | 100 nmol ×5 |
| GC3006-01 | HySOx | 20 μg × 5 |
| GC3007-01 | HYDROP | 30 nmol × 3 |
| GC3008-01 | HYDROP-EX | 30 nmol × 3 |
| FRETFluor™ Series | FRET based fluorescent probes | Size |
| A401-1 | QuicGSH3.0 | 25 nmol × 5 |
| A401-2 | QuicGSH3.0 | 25 nmol × 2 |
| A402-1 | SSip-1 DA | 60 nmol × 3 |
| NIRFluor™ series | Near infrared fluorescent probes | |
| A501-01 | ICG-NHS ester | 1 mg |
| A501-05 | ICG-NHS ester | 1 mg × 5 |
| A501-10 | ICG-NHS ester | 1 mg × 10 |
| A502-01 | ICG-maleimide | 1 mg |
| A502-05 | ICG-maleimide | 1 mg × 5 |
| A502-10 | ICG-maleimide | 1 mg × 10 |
| Bioluminescent series | Fluorescent probes for in vivo imaging | Size |
| RS101-01 | D-Luciferin potassium salt | 1 g |
| POLARIC™ Series | Fluorescent probes for staining cell membrane and bacteria | Size |
| GC101 | POLARIC™-500c6F | 1 μg × 10 |
| GC1011 | POLARIC™-500c6F | 1 μg × 5 |
| GC102 | POLARIC™-500BCS | 5 μg × 10 |
| GC1021 | POLARIC™-500BCS | 5 μg × 5 |
| GC2021 | POLARIC™-NHS | 1 mg |
| GC2031 | POLARIC™-maleimide | 1 mg |
| GC211 | POLARIC™ Labeling Kit | 5 times labelng |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="GORYO Chemical"> GORYO Chemical
艾美捷科技代理Schircks Laboratories品牌。
瑞士Schircks Laboratories由B.Schircks博士于1980年创立,主要生产蝶啶及蝶啶类化合物(Pteridines)。至今,Schircks实验室合成了100多种蝶啶类化合物,主要用于科学研究和临床诊断应用。产品包括:
<| 11.180 | 6-(L-1,2,3-Trihydroxybutyl)-pterin [Rhamnopterin] |
| 11.182 | (6R,S)-5,6,7,8-Tetrahydro-L-rhamnopterin dihydrochloride |
| 11.203 | L-Biopterin [L-erythro-Biopterin] |
| 11.206 | 7,8-Dihydro-L-biopterin |
| 11.209 | (6R,S)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride |
| 11.212 | (6R)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride |
| 11.213 | (6R)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride |
| 11.215 | (6S)-5,6,7,8-Tetrahydro-L-biopterin sulfate |
| 11.216 | (6S)-5,6,7,8-Tetrahydro-L-biopterin sulfate |
| 11.217 | (6R)-5-Methyl-5,6,7,8-tetrahydro-L-biopterin dihydrochloride |
| 11.218 | D-Biopterin [D-erythro-Biopterin] |
| 11.220 | (6R,S)-5,6,7,8-Tetrahydro-D-biopterin dihydrochloride |
| 11.221 | D-threo-Biopterin [Dictyopterin] |
| 11.223 | (6R,S)-5,6,7,8-Tetrahydro-D-threo-biopterin dihydrochloride |
| 11.228 | Deoxysepiapterin |
| 11.229 | 6-((1R,S)-Hydroxypropyl)pterin [(1'R,S)-2'-Deoxybiopterin] |
| 11.231 | 7-Biopterin |
| 11.234 | 7-Tetrahydro-L-biopterin dihydrochloride |
| 11.260 | Oncopterin |
| 11.270 | 4-Hydroxy-6-(L-erythro-1,2-dihydroxy-propyl)-2-(methylthio)pteridine |
| 11.280 | 4-Amino-L-biopterin [2,4-Diamino-6-(L-erythro-1',2'-dihydroxypropyl)pteridine] |
| 11.282 | 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride |
| 11.283 | 4-Amino-(6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride |
| 11.303 | D-Neopterin [D-erythro-Neopterin] |
| 11.306 | 7,8-Dihydro-D-neopterin |
| 11.307 | 7,8-Dihydro-D-neopterin-3’-triphosphate (Please refer to our reference 8) |
| 11.309 | (6R,S)-5,6,7,8-Tetrahydro-D-neopterin dihydrochloride |
| 11.314 | D-Neopterin-3’-monophosphate, lithium salt |
| 11.315 | 7,8-Dihydro-D-neopterin-3’-monophosphate, lithium salt |
| 11.320 | 3'-Hydroxy-D-sepiapterin |
| 11.330 | 7-Neopterin |
| 11.340 | L-Monapterin [L-threo-Neopterin] |
| 11.345 | 7,8-Dihydro-L-monapterin |
| 11.346 | (6R,S)-5,6,7,8-Tetrahydro-L-monapterin dihydrochloride |
| 11.349 | D-Monapterin [D-threo-Neopterin] |
| 11.403 | Pterin-6-carboxylic acid |
| 11.409 | Pterin-7-carboxylic acid |
| 11.415 | 6-Formylpterin [Pterin-6-aldehyde] |
| 11.416 | 6-Formyl-7,8-dihydropterin |
| 11.418 | Acetyl-6-formylpterin |
| 11.420 | 6-Hydroxymethylpterin |
| 11.421 | 6-Hydroxymethyl-7,8-dihydropterin hydrochloride |
| 11.422 | 6-Hydroxymethyl-7,8-dihydropterin-diphosphate (Please refer to our reference 8) |
| 11.423 | (6R,S)-6-Hydroxymethyl-5,6,7,8-tetrahydropterin dihydrochloride |
| 11.429 | 6-Hydroxymethylpterin-monophosphate |
| 11.438 | 6-Hydroxymethylpterin-diphosphate, lithium salt |
| 11.480 | 6-Methylpterin |
| 11.481 | 6-Methyl-7,8-dihydropterin hydrochloride |
| 11.483 | (6R,S)-6-Methyl-5,6,7,8-tetrahydropterin dihydrochloride |
| 11.503 | 6,7-Dimethylpterin |
| 11.506 | 6,7-Dimethyl-7,8-dihydropterin monohydrochloride |
| 11.509 | 6,7-Dimethyl-5,6,7,8-tetrahydropterin monohydrochloride |
| 11.703 | Leucopterin |
| 11.713 | Xanthopterin |
| 11.716 | Dihydroxanthopterin |
| 11.723 | Isoxanthopterin |
| 11.903 | Pterin |
| 11.906 | 7,8-Dihydropterin (Please refer to our reference 20) |
| 11.909 | 5,6,7,8-Tetrahydropterin dihydrochloride |
| 13.103 | Lumazine |
| 13.203 | 6-Hydroxylumazine |
| 13.206 | 6-Hydroxy-7,8-dihydrolumazine |
| 13.220 | 7-Hydroxylumazine |
| 16.113 | Pteroic acid |
| 16.123 | N10-(Trifluoroacetyl)pteroic acid |
| 16.140 | 10-Formylpteroic acid |
| 16.203 | Folic acid |
| 16.206 | 7,8-Dihydrofolic acid |
| 16.208 | (6S)-5,6,7,8-Tetrahydrofolic acid trihydrochloride |
| 16.209 | (6R,S)-5,6,7,8-Tetrahydrofolic acid trihydrochloride |
| 16.211 | 10-Methylfolic acid |
| 16.215 | 10-Formylfolic acid |
| 16.217 | 10-Formyl-5,6,7,8-tetrahydrofolic acid (Please refer to our reference 19) |
| 16.220 | (6R,S)-5-Formyl-5,6,7,8-tetrahydrofolic acid, calcium salt |
| 16.222 | (6R)-5-Formyl-5,6,7,8-tetrahydrofolic acid, calcium salt (unnatural calcium folinate) |
| 16.230 | (6R,S)-5,10-Methenyl-5,6,7,8-tetrahydrofolic acid chloride |
| 16.233 | (6R,S)-5-Methyl-5,6-dihydrofolic acid, ammonium salt |
| 16.235 | (6R,S)-5-Methyl-5,6,7,8-tetrahydrofolic acid, calcium salt |
| 16.236 | (6S)-5-Methyl-5,6,7,8-tetrahydrofolic acid, calcium salt |
| 16.243 | (6R,S)-5-Methyl-5,6,7,8-tetrahydropteroyltri-γ-L-glutamic acid trihydrochloride |
| 16.244 | (6R,S)-5-Methyl-5,6,7,8-tetrahydropteroyltetra-γ-L-glutamic acid trihydrochloride |
| 16.252 | Pteroyldi-γ-L-glutamic acid |
| 16.253 | Pteroyltri-γ-L-glutamic acid has been discontinued |
| 16.254 | Pteroyltetra-γ-L-glutamic acid |
| 16.255 | Pteroylpenta-γ-L-glutamic acid has been discontinued |
| 16.266 | Pteroylhexa-γ-L-glutamic acid, ammonium salt |
| 16.267 | Pteroylhepta-γ-L-glutamic acid, ammonium salt |
| 16.280 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroic acid |
| 16.282 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroyldi-γ-L-glutamic acid, lithium salt has been discontinued |
| 16.283 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroyltri-γ-L-glutamic acid, lithium salt has been discontinued |
| 16.284 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroyltetra-γ-L-glutamic acid, lithium salt |
| 16.285 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroylpenta-γ-L-glutamic acid, lithium salt |
| 16.286 | (6R,S)-5-Formyl-5,6,7,8-tetrahydropteroylhexa-γ-L-glutamic acid, lithium salt |
| 16.330 | Aminopterin [4-Aminofolic acid] |
| 16.403 | 4-Amino-10-methylpteroic acid (APA, DAMPA) |
| 16.411 | Methotrexate [4-Amino-10-methylpteroyl-γ-L-glutamic acid] |
| 16.412 | 4-Amino-10-methylpteroyldi-γ-L-glutamic acid, ammonium salt [Methotrexate diglutamate] |
| 16.413 | 4-Amino-10-methylpteroyltri-γ-L-glutamic acid, ammonium salt [Methotrexate triglutamate] |
| 16.414 | 4-Amino-10-methylpteroyltetra-γ-L-glutamic acid, ammonium salt [Methotrexate tetraglutamate] |
| 16.415 | 4-Amino-10-methylpteroylpenta-γ-L-glutamic acid, ammonium salt [Methotrexate pentaglutamate] |
| 16.416 | 4-Amino-10-methylpteroylhexa-γ-L-glutamic acid, ammonium salt [Methotrexate hexaglutamate] |
| 16.417 | 4-Amino-10-methylpteroylhepta-γ-L-glutamic acid, ammonium salt [Methotrexate heptaglutamate] |
| 16.500 | 7-Hydroxymethotrexate |
| 16.701 | p-Aminobenzoyl-L-glutamic acid |
| 16.702 | p-Aminobenzoyldi-γ-L-glutamic acid, ammonium salt |
| 16.703 | p-Aminobenzoyltri-γ-L-glutamic acid, ammonium salt |
| 16.704 | p-Aminobenzoyltetra-γ-L-glutamic acid, ammonium salt |
| 16.705 | p-Aminobenzoylpenta-γ-L-glutamic acid, ammonium salt |
| 16.706 | p-Aminobenzoylhexa-γ-L-glutamic acid, ammonium salt |
| 16.707 | p-Aminobenzoylhepta-γ-L-glutamic acid, ammonium salt has been discontinued |
| 16.901 | Z-Glu-OtBu |
| 16.902 | Z-Glu2-OtBu3 |
| 16.903 | Z-Glu3-OtBu4 |
| 16.904 | Z-Glu4-OtBu5 |
| 16.905 | Z-Glu5-OtBu6 |
| 16.906 | Z-Glu6-OtBu7 |
| 91.303 | D-(5-15N)-Neopterin |
| 96.203 | (5-15N)-Folic acid |

SurModics公司成立于1979年,拥有30多年的临床诊断、生物医药、科研产品研发和开发经验,是体外诊断技术的领先品牌。可提供多种产品,主要包括蛋白稳定剂、封闭剂、缓冲剂、比色底物及化学发光底物、和抗原、抗体等。
Surmodics is the global leader in surface modification technologies for vascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two acquisitions of Creagh Medical and NorMedix – recognized innovators in balloon catheters and delivery systems – we have combined capabilities in proprietary surface technologies, as well as device design, development and manufacturing that enable us to significantly increase the value we offer our medical device customers. We are focused on developing highly differentiated, total vascular device solutions to the most demanding clinical challenges. The company’s R&D pipeline is rich with novel innovations within the field of vascular medicine. Even as we expand our capabilities, our mission remains to improve the detection and treatment of disease.
Surmodics公司主要产品:
(1)蛋白稳定剂/封闭剂
免疫检测稳定剂(微量滴定板、乳胶小珠、磁珠);微阵列芯片稳定剂; 封闭剂;结合物稳定剂(AP,HRP);无BSA稳定剂;稳定剂包:包含免疫检测稳定剂、结合物稳定剂、无BSA稳定剂、可选择稳定剂各25ml。
(2)BioFX底物/终止剂
比色HRP底物、比色AP底物、化学发光HRP底物、化学发光AP底物、TMB底物、ABTS和pNPP底物。
(3)稀释液/缓冲液/IHC试剂/附属试剂
SurModics提供ELISA稀释液、清洗液、免疫组化试剂。
(4)DIARECT自身免疫和免疫疾病抗原
DIARECT自勉和免疫疾病抗原的质量和敏感性都经过校验。主要包括:ANCN相关疾病、自勉型肝炎和肝脏疾病、肾炎综合症、甲状腺自勉疾病、血栓栓塞综合症、莱姆病、肠炎、胃肠腹腔疾病、细小病毒等。
(5)BioFX抗体和链酶亲和素
SurModics IVD为免疫印迹、免疫组化、ELISpot、RIA、微阵列应用提供十种不同物种和六种宿主二抗。
(6)微阵列芯片
微阵列芯片通过共价键链接RNA、DNA和蛋白,使用方便,兼容性好,适用于大部分阵列和扫描设备。
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://lifesensors.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Surmodics"> Surmodics地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:18771149750
邮箱:sales@amyjet.com
0.3185